It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Understand when rebalancing triggers capital gains taxes and how to plan for them. This intro highlights key rules and proactive strategies.
23,600 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
A Monday surge put Archer Aviation stock in the spotlight as investors reacted to major eVTOL news. This guide breaks...
In 2025, Marathon Petroleum delivered a powerful cash-return story for shareholders. This article breaks down how the...
A major trading move shows Clearline Capital expanding its Core Scientific holding just as Bitcoin mining evolves int...
Awards shine briefly, but investors chase cash flow, growth, and disciplined capital allocation. This guide shows how...
A Texas Capital BancShares board member purchased 1,000 shares at $91.50 per share as the stock price weakened. This ...
A quiet, data-driven move by Endeavour Capital Advisors boosted its stake in QCR Holdings in Q1 2026. Learn what this...
A mobility startup defies the VC playbook, raising $15 million from private investors. The story highlights disciplin...
SpaceX's IPO hype is hard to ignore, but there are four solid concerns investors should weigh before buying in. This ...
Alphabet’s billion flex is more than just cash. It’s a strategic playbook that powers buybacks, AI investments, and l...
A wave of consolidation in homebuilding is driven by scale and access to the foreign capital market, reshaping how de...
Warren Buffett publicly stated he initiated Berkshire Hathaway’s larger stake in Alphabet, signaling a top-down push ...